JamesScottMcClellanMD

PubMed

• 36 citations
  Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma
  A. Keith Stewart, Amrita Krishnan, Seema Singhal, Ralph V. Boccia, Manish R. Patel, Ruben Niesvizky, Asher Chanan-Khan, Sikander Ailawadhi, Jochen Brumm, Kirsten Mundt...> ;Blood Cancer Journal. 2019 Feb 4
• 1 citations
  Reply to Fišer et al.: Myeloid reprogramming of Ph+ B-ALL: A potential therapeutic strategy.
  Ravindra Majeti, Christopher Dove, James Scott McClellan> ;Proceedings of the National Academy of Sciences of the United States of America. 2015 Jul 7
• 41 citations
  Reprogramming of primary human Philadelphia chromosome-positive B cell acute lymphoblastic leukemia cells into nonleukemic macrophages
  James Scott McClellan, Christopher Dove, Andrew J. Gentles, Christine E. Ryan, Ravindra Majeti> ;Proceedings of the National Academy of Sciences of the United States of America. 2015 Mar 31
• 6 citations
  The cancer stem cell model: B cell acute lymphoblastic leukaemia breaks the mould.
  James Scott McClellan, Ravindra Majeti> ;EMBO Molecular Medicine. 2013 Jan 1
• 3 citations
  Cryptococcal osteomyelitis and meningitis in a patient with non-hodgkin’s lymphoma treated with PEP-C
  Christina A. To, Robert W. Hsieh, James Scott McClellan, Walter Howard, Nancy J. Fischbein, Janice M. Brown, Dean W. Felsher, Alice C. Fan> ;BMJ Case Reports. 2012 Sep 7
• 111 citations
  Treatment advances have not improved the early death rate in acute promyelocytic leukemia
  James Scott McClellan, Holbrook E Kohrt, Steve S. Coutre, Jason Gotlib, Ravindra Majeti, Ash A. Alizadeh, Bruno C. Medeiros> ;Haematologica. 2012 Jan 1
• Join now to see all